China Biotech Services Holdings Limited provided unaudited consolidated earnings guidance for the nine months ended 30 September 2022. For the period, the company expects to record a net profit attributable to the owners of the Company (Net Profit) of not less than HKD 150,000,000 for the 2022 third quarter Period as compared with that of approximately HKD 27,254,000 recorded for the corresponding period in 2021. The Board considers that such an increase of the Net Profit for 2022 third quarter Period was mainly attributable to the robust demands for rapid antigen test kits and COVID-19 testing services during the period due to the raging fifth wave of COVID-19 pandemic, and the increase in demand for COVID-19 testing services from cross-border or overseas passengers due to the easing of border restrictions.